The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients
Status:
RECRUITING
Trial end date:
2025-12-05
Target enrollment:
Participant gender:
Summary
This is a prospective, open-labled, randomized controlled study to assess efficacy and safety of treatment with Sintilimab (PD-1 antibody) combined Peg-IFNα-2b in CHB patients on stable NAs treatment.